Home Learn Safety matrix

— Side effects, contraindications, interactions

The whole safety picture, fourteen rows.

Compiled from peer-reviewed literature, our advisor panel's clinical judgment, and field reports from patients running self-experiments. We mark frequency as commonly observed (≥1 in 10), occasional (1–10%), or rare (<1%). Severity is editorial — a 'critical' tag means stop and call a clinician.

Tolerable Notable Serious Critical / stop

— 01

Retatrutide

GLP-1/GIP/Glucagon agonist GI common

SIDE EFFECTS

Nausea & GI upsetDose-dependent. Mitigate with slow titration (start 1mg/wk, +1mg every 4 wk).
Common
Decreased appetiteExpected pharmacology; problematic if it leads to under-eating <1500 kcal/d.
Common
Heart-rate elevationResting HR +5–10 bpm in trials. Track at home; pause if >90 bpm sustained.
Occasional
PancreatitisSevere persistent epigastric pain → discontinue immediately, seek care.
Rare
GallstonesRapid weight loss is a known precipitator. Monitor RUQ pain.
Rare

CONTRAINDICATIONS

Personal/family history MEN2 or MTCBoxed warning analog to other GLP-1s.
Severe gastroparesisWill be amplified.
Type 1 diabetes (insulin-dependent)Off-label without supervision; hypoglycemia risk.

DRUG & SUBSTANCE INTERACTIONS

Insulin & sulfonylureasReduce concomitant dose 25% on initiation; hypoglycemia risk.
Oral medications generallyDelayed gastric emptying alters absorption — re-check INR, levothyroxine, oral contraceptives.

Cross-reference: Retatrutide · Citations Field reports: 38 entries

— 02

Tirzepatide

GLP-1/GIP dual agonist GI common

SIDE EFFECTS

Nausea, diarrhea, constipationHighest in first 4 weeks of titration.
Common
Injection-site reactionMild redness at SQ site. Rotate sites weekly.
Common
FatigueOften resolves within 2–3 weeks of dose stability.
Occasional
PancreatitisSame risk profile as semaglutide and retatrutide.
Rare
Acute kidney injuryVolume depletion from severe nausea/vomiting → AKI.
Rare

CONTRAINDICATIONS

MEN2 or MTC historyBoxed warning.
Pancreatitis historyDocumented prior episode → contraindicated.
Severe hepatic impairmentLimited data; consult prescriber.

DRUG & SUBSTANCE INTERACTIONS

Insulin/sulfonylureasPre-emptive dose reduction.
Oral contraceptivesUse barrier method for 4 wk after each dose escalation.
WarfarinMonitor INR more frequently.

Cross-reference: Tirzepatide · Citations Field reports: 24 entries

— 03

Semaglutide

GLP-1 agonist GI common

SIDE EFFECTS

NauseaMost common in titration phase.
Common
Decreased appetiteExpected.
Common
Diabetic retinopathy progressionIn pre-existing retinopathy with rapid HbA1c drop. Baseline eye exam recommended.
Occasional
PancreatitisDiscontinue if confirmed.
Rare

CONTRAINDICATIONS

MEN2 or MTC historyBoxed warning.
Severe gastroparesisWill worsen significantly.

DRUG & SUBSTANCE INTERACTIONS

Insulin/sulfonylureasHypoglycemia risk.
LevothyroxineDelayed absorption — re-check TSH 6–8 weeks after start.

Cross-reference: Semaglutide · Citations Field reports: 52 entries

— 04

Larazotide

TIGHT JUNCTION REGULATOR MILD PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: Larazotide · Citations Field reports: 8 entries

— 05

BPC-157

Body protection compound Mild profile

SIDE EFFECTS

Injection-site itchingResolves within hours.
Rare
Mild dizzinessReported in <1% of field reports.
Rare

CONTRAINDICATIONS

Active malignancyTissue-growth properties — caution in any active oncologic disease.

DRUG & SUBSTANCE INTERACTIONS

No documented drug interactionsLimited research; theoretically additive with growth factors.

Cross-reference: BPC-157 · Citations Field reports: 16 entries

— 06

Epitalon

TELOMERE REGULATOR MILD PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: Epitalon · Citations Field reports: 4 entries

— 07

NAD+

COENZYME MILD PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: NAD+ · Citations Field reports: 22 entries

— 08

Ipamorelin / CJC-1295

GH SECRETAGOGUE NOTABLE PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: Ipamorelin / CJC-1295 · Citations Field reports: 14 entries

— 09

GLOW Blend

COSMETIC PEPTIDE MILD PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: GLOW Blend · Citations Field reports: 6 entries

— 10

MOTS-c

MITOCHONDRIAL PEPTIDE MILD PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: MOTS-c · Citations Field reports: 10 entries

— 11

Tesamorelin

GHRH ANALOG NOTABLE PROFILE

SIDE EFFECTS

Please configureAdd specific medical side effects via the Shopify editor to replace this placeholder.
N/A

CONTRAINDICATIONS

Cross-reference: Tesamorelin · Citations Field reports: 9 entries

— 12

TB-500

Thymosin β-4 fragment Mild profile

SIDE EFFECTS

Mild lethargy first 48hOften called the "TB flu"; resolves quickly.
Occasional
Injection-site sorenessMild.
Rare

CONTRAINDICATIONS

Active malignancySame caution as BPC-157.
WADA banned substanceFor competitive athletes — research use only, do not dose.

DRUG & SUBSTANCE INTERACTIONS

No documented interactionsLimited literature.

Cross-reference: TB-500 · Citations Field reports: 19 entries

— 13

GHK-Cu

Copper tripeptide Topical-leaning

SIDE EFFECTS

Skin irritation (topical)In sensitive skin. Patch-test 24h before broader use.
Occasional
Copper accumulationTheoretical with chronic high-dose. Watch in Wilson disease.
Rare

CONTRAINDICATIONS

Wilson diseaseImpaired copper metabolism — categorical.
Active melanomaPigmentation effects unclear.

DRUG & SUBSTANCE INTERACTIONS

PenicillamineChelating agents reduce copper bioavailability.

Cross-reference: GHK-Cu · Citations Field reports: 11 entries

— 14

KPV

Anti-inflammatory tripeptide Mild profile

SIDE EFFECTS

Mild GI upset (oral)Resolves with food.
Rare
Injection-site reactionMinor.
Rare

CONTRAINDICATIONS

Severe immunocompromiseAnti-inflammatory effect may mask infection signs.

DRUG & SUBSTANCE INTERACTIONS

No documented interactionsLimited literature.

Cross-reference: KPV · Citations Field reports: 7 entries

— Universal contraindications

These apply to every compound on this site.

Pregnancy & lactation

No peptide on this site has adequate human safety data in pregnancy or breastfeeding. Categorical contraindication, no exceptions.

Active malignancy

Growth-factor and GH-axis activity is not appropriate in active cancer or recent (5-year) history of MEN2/MTC. See per-compound notes for exceptions.

Under 18

Insufficient pediatric safety data across the full panel. We do not ship to or accept research-use attestations from minors.

Active infection

Pause regenerative peptides during acute bacterial or viral infection. GLP-1 family is acceptable but watch for additive nausea.

Concurrent polypharmacy

Insulin, sulfonylureas, GH replacement, blood thinners, immunosuppressants — review the per-compound interaction list and consult a prescriber.

Allergy to excipients

Mannitol (most lyo cakes), benzyl alcohol (BAC water), m-cresol (some formulations). Spot-check the COA before reconstituting.

— Cross-references

Pair this with the storage & technique guides.

Most adverse events we see in field reports trace back to dose math errors or contaminated reconstitution — not the molecule itself.

Reconstitution guide Storage guide Dosing calculator